Aprecia is the global leader in commercial-scale 3DP for pharmaceutical manufacturing technology. We’re committed to creating new solutions for unmet healthcare needs by developing pharma-ready innovations and complementary technology platforms that enable patient-centric products and help take medicine to its fullest potential.
At Aprecia, we strive every day to imagine, inspire, and transform the new age of digital medicine.
Aprecia is a unique drug delivery technology platform company that’s committed to transforming the patient and caregiver experience by reducing pill burden or simply making medicines easier to take. We imagine a world where medications are no longer challenging for patients to take or for caregivers to give. And we inspire each other every day to seek innovative solutions that address administration and adherence needs.
Built upon our proprietary three-dimensional printing (3DP) technology platform, we focus on opportunities where there is a need for medicines that are easy to take. Aprecia is the first and only company in the world utilizing this cutting-edge 3DP technology platform to develop and manufacture pharmaceutical products on a commercial scale. We believe our platform will generate multiple product-enhancing drug delivery technologies that can be used across all therapeutic categories. Our first innovation that leverages 3DP is ZipDose® Technology and is uniquely able to accommodate a high dosage load (over 1000 mg of active pharmaceutical ingredient) in a rapidly orodispersible tablet with a wide range of taste masking capabilities. With these capabilities, ZipDose Technology is redefining the fast-melt market.
New solutions and new possibilities for patients and caregivers in the new digital age of medicine
Never stop exploring ways to take medicine to it’s fullest potential
Establish 3DP technology as a true digital pharmaceutical manufacturing technology
Aprecia, the 3DP Pharmaceutical Company, is a privately held pharmaceutical technology company led by a seasoned, highly motivated team of individuals who have been contributing to the advancement of pharmaceuticals over the course of their careers.
Mr. Arington has served as a member of the Aprecia Pharmaceuticals Board of Directors since 2010 and as Chairman of the Board since 2011. His vision for three-dimensional printing in pharmaceuticals spans more than 20 years. Mr. Arington has spent his lifetime in the pharmaceutical industry, significantly contributing to the advancement of pharmaceuticals in multiple companies and roles.
Chief Executive Officer
Dr. Tracy is an expert in clinical pharmacology and a Fellow with the American Association of Pharmaceutical Scientists. He holds two patents related to drug delivery systems and has published over 100 scientific manuscripts. Dr. Tracy has held numerous key positions at state universities and brings significant leadership competencies to Aprecia.
Chief Financial Officer & SVP of Business Operations
Mr. Rohlfs has served as Aprecia’s Chief Financial Officer since July 2013 and brings over 20 years of experience in the pharmaceutical industry. Mr. Rohlfs’ career has been focused in the areas of strategic planning, finance, business operations and business analytics while serving in progressive management and leadership roles including:
Chief Technology Officer
Dr. Yoo started his 3DP journey at MIT in 1991, investigating various applications of then nascent technology with unlimited potential. Since then, he has pioneered numerous applications of 3DP in pharmaceutical and tissue repair fields, resulting in 18 issued US patents as well as several pending patent applications. Dr. Yoo’s pharmaceutical industry experience spans more than 20 years and includes key roles such as:
Senior Executive Advisor & SVP
Mr. Wetherhold brings 30 years of experience in the pharmaceutical and healthcare industry, and today serves as a key strategist and advisor to the senior executive team at Aprecia. Mr. Wetherhold previously served as the company’s Chief Executive Officer (2013 – 2017) and has held numerous leadership positions across the pharmaceutical value chain throughout his career.
Chief Operating Officer
Mr. Williford has served as Chief Operating Officer since February 2013, preceded by various consulting roles with Aprecia during key growth years. Mr. Williford has made significant contributions to the transition from a scientific invention company to a commercial manufacturing company. Mr. Williford’s pharmaceutical experience spans 30 years over key leadership positions including:
Senior Vice President
Dr. Fort has considerable scientific experience in areas of pre-formulation, formulation and product design and development and has impacted numerous NDA applications, consumer products, and an Rx to OTC switch. With his Bachelors in Pharmacy from Duquesne University and his Ph.D. in Physical Pharmacy from Purdue University, Dr. Fort’s career spans 29 years in the pharmaceutical industry including key roles such as:
Mr. Glassmann has served as legal counsel and senior executive business support for Aprecia since 2008. In addition, Mr. Glassmann served as a member of Aprecia Pharmaceuticals’ Board of Directors from 2009 to 2017. Mr. Glassmann earned his J.D. degree with Honors from The Ohio State University College of Law and his B.A., Summa Cum Laude and with High Honors, from the University of Cincinnati. In a legal career that spans more than 30 years, Mr. Glassmann has held both inside and outside counsel roles specializing in making deals and resolving litigation for the global pharmaceutical industry.
Dr. Mahendra Patel has been a key scientific advisor to Aprecia since 2003. Along with Mr. E Thomas Arington, Dr. Patel has shared a vision for the future of pharmaceutical manufacturing. His expertise has been instrumental in product and equipment design through commercial viability. Dr. Patel’s career includes strategic roles across the industry including:
Aprecia Pharmaceuticals was founded in 2003 with the explicit goal of achieving commercial production for unique pharmaceutical dosage forms via advanced three-dimensional printing (3DP) technology. Powder-liquid 3DP, a novel technology that forms objects layer by layer, was originally developed at the Massachusetts Institute of Technology (MIT) in the late 1980s as a rapid-prototyping technique. From 1993 to 2003, this work was expanded into the distinct areas of tissue engineering and pharmaceuticals. While 3DP technology rights were licensed for a diverse range of industrial fields, MIT's 3DP process and its applications in the pharmaceutical industry are exclusively licensed to Aprecia.
In 2007, we began developing our orodispersible platform, known as ZipDose® Technology. ZipDose® formulations bring easy-to-swallow functionality to high-dose medications, overcoming challenges unaddressed by prior technologies. Our vision: to enhance patients' experience with highly prescribed high-dose medications.
In 2008, Aprecia began working with a proprietary forming system that enhances manufacturing efficiency and output in the 3DP process. This enabled us to achieve our initial goal of reaching commercial production for our 3DP formulations.
This initiative continued through 2011, when we further refined this process to prepare for commercialization of the 3DP and ZipDose® Technology platform in a cGMP facility.
In 2011, Aprecia also began operations at our facility in East Windsor, NJ.
In 2015, Aprecia's first 3D printed drug product was approved by the FDA.Aprecia continues to add manufacturing capacity and additional sites to support our expanding product pipeline and enhance our commercial capacity.
ZipDose® Technology development begins
Proprietary 3DP forming system built
Registration and launch facility opens in East Windsor, NJ
Filing of first NDA with the FDA
First product approved by US FDA; initiated commercial manufacturing operations at East Windsor, NJ
First and only FDA-approved 3D printed product launched in the US
New high throughput commercial scale equipment qualified
New Ohio GMP manufacturing site inspected and approved for Spritam production
Additional patents issued and filed
New development scale equipment qualified